Comparison of goserelin and leuprolide in combined androgen blockade therapy

What Was Tested

Researchers studied Leuprolide and Goserelin in this randomized controlled trial publication.

One analysis compared goserelin plus antiandrogen therapy with leuprolide plus antiandrogen therapy; a second analysis compared the four combined androgen blockade (CAB) regimens.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults, older adults and people over 80, men only.

How the Study Was Run

In design terms this was a randomized, double-blind, open-label and multicenter study.

The participants were allocated by chance, so the Leuprolide group and the comparison group should start out alike.

As a double-blind Leuprolide study, the assignments were hidden from both participants and investigators until the end.

Being open-label, the Leuprolide study did not mask who received what.

More than one site took part, so the participants came from several places.

This was a randomized, multicenter trial, open-label for luteinizing hormone releasing hormone analogue (LHRH-A) therapy, double-blind for antiandrogen therapy, with a two-by-two factorial design.

The end points of time to progression and survival were assessed with a median of 160 weeks of follow-up.

What Was Measured

Topics PubMed links to this paper include Androgen Antagonists, Anilides, Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Flutamide and Goserelin.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Leuprolide and Goserelin.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1998 (Urology), a journal based in United States.

More context: the Leuprolide compound page and the Goserelin compound page, all human trials.